Nat Commun: Cancer vaccine may effectively overcome cancer cell resistance to therapy

In the clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ) conducted by researchers, several patients initially achieved initial response, but then their disease relapsed

A few days ago, in a research report entitled "Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy" published in the international journal Nature Communications, scientists from the Mayo Clinic and other institutions found that one This kind of cancer vaccine may be an effective way to prevent cancer from evolving and to develop resistance to therapies

Image source: https:// the article, the researchers investigated a virus that kills cancer cells in clinical trials.

In this research report, researchers have shown for the first time that this type of vaccine may be used to overcome the evolution and tolerance of cancer; it is well known that the use of anti-cancer viruses to treat tumor cells may cause mutations and promote cancer cell evolution.

The mutation produced by the CDSE1 gene CDSE1 protein produces a unique antigen (this structure is recognized as a target by the immune system), which helps researchers develop new vaccines; researchers have developed a mutation that can target this mutation And found that the injection of this vaccine into the body of mice treated with the virus may induce the immune system to destroy the drug-resistant tumor cells and kill the cancerous cells, thereby reducing the size of the tumor

CSDE1 is a positive regulator of vesicular stomatitis virus replication

Image source: Kottke, T.

Researchers use the tumor's defense mechanism by vaccinating mutant cells.

This principle may be widely applicable, because tumor resistance to drugs is a big problem faced by many types of therapies.

Original source:

Kottke, T.

This article is from Bio Valley, for more information, please download the Bio Valley APP (http://